*ST生物: 南华生物关于授权经营层挂牌出售子公司股权的公告

Transaction Overview - The company plans to sell 52% equity of its subsidiary, Nanhua Peace Hospital Management (Hunan) Co., Ltd., through public listing on Hunan United Property Exchange to optimize its business structure [1][4] - The sale price will be based on the asset's evaluation results and will not be lower than the assessed value [1][4] Financial Performance - As of December 31, 2024, the company reported total revenue of approximately 31.81 million [3] - The company incurred a total profit loss of approximately 2.19 million and a net profit loss of approximately 2.31 million [3] - Total assets were approximately 153.92 million, with total liabilities of approximately 96.27 million, resulting in net assets of approximately 57.66 million [3] Transaction Details - The transaction does not currently have a confirmed buyer, and the company will disclose the buyer's information as the public listing progresses [1][4] - The company will sign a share transfer agreement with the confirmed buyer based on the public listing results [4] Impact on the Company - The transfer of the subsidiary's equity aligns with the company's overall operational development needs and does not harm the interests of the company and its shareholders [4] - The evaluation of Nanhua Peace is ongoing, and the company will comply with relevant regulations and disclose information in a timely manner [4][5]